Dr. Erin LeBlanc is an epidemiologist and board-certified adult endocrinologist. Her research focuses on conditions that affect women, including menopause, obesity, osteoporosis, diabetes, and vitamin D deficiency.
In 2011, Dr. LeBlanc led a systematic evidence review on obesity to support the U.S. Preventive Services Task Force. In 2014, she led a systematic evidence review regarding screening for vitamin D deficiency. Currently, she is leading the D2d study, a multicenter study examining the effects of vitamin D on diabetes risk, at the Portland site. D2d is. She led a study examining risk factors associated with fractures among people taking bisphosphonates. She is also a co-investigator on the Prepare study, which is examining the effects of a pre-pregnancy weight loss program, and on de por vida, which is examining the effects of a weight loss intervention in Hispanics with diabetes or prediabetes.
Dr. LeBlanc is a co-investigator on the Study of Osteoporotic Fractures (SOF), a nearly 30-year-old study that is linking its database with Medicare claims data for nearly 10,000 women to examine relationships between aging and cognitive function, physical performance, bone mineral density, and body weight.
Dr. LeBlanc came to CHR in 2009 from Oregon Health & Science University (OHSU), where she proposed a randomized trial testing the efficacy of vitamin D repletion on body composition in perimenopausal women. She served as the Principal Investigator for the Women’s Health Initiative study, which examined heart disease, cancer, and osteoporosis in postmenopausal women.
Dr. LeBlanc graduated cum laude from the Yale University School of Medicine. Following her internal medicine residency at Stanford University and before joining OHSU, she completed fellowships in women’s health and endocrinology at the Portland VA Medical Center and Oregon Health & Science University. She remains an affiliate assistant professor of endocrinology at OHSU.